Derek Letort, MD
Neurology · Jackson, MSNPI 1023202272
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 1,274 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 8.7% — the pattern of someone who eats at a lot of different presentations.
Across 1,274 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Pfizer$1K
- Teva Pharmaceuticals USA, Inc.$1K
- SK Life Science, Inc.$1K
- Acadia Pharmaceuticals Inc$1K
- UCB, Inc.$1K
- plus $17K from 54 others
What the payments were for
- Speaking & faculty fees$2971%
- Food & beverage$25,02199%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,345 in reported general payments places this provider in the 80th percentile of 111 neurology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 16 | $248,497 |
| IngrezzaValbenazine Tosylate | 14 | $120,195 |
| TysabriNatalizumab | 13 | $106,689 |
| TecfideraDimethyl Fumarate | 12 | $105,552 |
| GocovriAmantadine Hcl | 31 | $54,828 |
| AptiomEslicarbazepine Acetate | 26 | $52,023 |
| NeuproRotigotine | 37 | $29,151 |
| XcopriCenobamate | 15 | $19,385 |
| FycompaPerampanel | 13 | $18,450 |
| Aimovig AutoinjectorErenumab-Aooe | 17 | $17,339 |
| Nurtec OdtRimegepant Sulfate | 18 | $16,776 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 704 | $15,963 |
| RytaryCarbidopa/Levodopa | 23 | $14,849 |
| Lacosamide | 183 | $14,389 |
| Entacapone | 47 | $11,004 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Nurtec Odt | $1,338 | $265,27334 claims |
| BiogenTysabri, Tecfidera | $970 | $212,24125 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $841 | $120,19514 claims |
| MDD US Operations, LLCGocovri | $1,037 | $54,82831 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $365 | $52,02326 claims |
| UCB, Inc.Neupro | $1,130 | $29,15137 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $262 | $20,71776 claims |
| SK Life Science, Inc.Xcopri | $1,194 | $19,38515 claims |
| Eisai Inc.Fycompa | $112 | $18,45013 claims |
| NovartisExelon | $964 | $8,77113 claims |
| Upsher-smith Laboratories LLCTopiramate | $281 | $2,274161 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 111 neurology providers in Mississippi.
Other neurology in Jackson
- Ruth FredericksJackson$943K
- Wendell HelvestonJackson$883K
- Rajesh SharmaJackson$152K
- Patrick WeldonJackson$85K
- Riichi OtaJackson$53K
- Mitchell MyersJackson$43K
- Tiffany ScarffJackson$29K
- Shreyas GangadharaJackson$20K
- Juebin HuangJackson$20K
- David McHenryJackson$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.